Date: Tuesday 06 Jan 2009
Shares in Ark Therapeutics are on the rise after the drug developer said the Marketing Authorisation Application (MAA) for Cerepro, its novel gene-based therapy for operable malignant, has cleared the validation stage.
The Cerepro MAA application now commences formal review.
"The acceptance of the Cerepro submission is a further significant milestone for Ark," said chief executive Nigel Parker.
Electronic component maker e2v Technologies is also going well on news that the group has won two contract renewals worth a total of £17m with delivery extending up to three years.
Both contracts are with existing Original Equipment Manufacturer (OEM) customers, and are for products from e2v's electron device and sub-systems division for use within radiotherapy cancer treatment systems.
“These anticipated multi-year contract renewals reflect the ongoing demand for new systems, as well as the need to service the growing number of in-service systems, and reinforces our position as a strategic supplier into the global radiotherapy equipment market,” said chief executive Keith Attwood.
FTSE TechMARK - Risers
Innovation Group (TIG) 6.27p +8.10%
Ark Therapeutics (AKT) 43.00p +7.50%
GB Group (GBG) 22.75p +7.06%
SDL International (SDL) 249.00p +6.41%
Elan Corporation (ELA) € 5.35 +4.09%
Corin Group (CRG) 52.00p +4.00%
E2V Technologies (E2V) 230.00p +3.60%
BATM Advanced (BVC) 37.25p +3.47%
Filtronic (FTC) 31.00p +3.33%
Vislink (VLK) 16.50p +3.12%
FTSE TechMARK - Fallers
Inion (IIN) 2.25p -28.12%
Redstone (RED) 6.00p -7.69%
NXT (NTX) 9.13p -6.36%
Morse (MOR) 7.80p -4.29%
Optos (OPTS) 73.00p -3.63%
Puricore (PURI) 8.00p -3.61%
Ricardo Group (RCDO) 220.25p -3.50%
Antisoma (ASM) 24.00p -3.03%
Vernalis (VER) 3.35p -2.33%
CML Microsystems (CML) 45.00p -2.17%
or share it with one of these popular networks:
You are here: news